ACADIA Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . ACADIA Pharmaceuticals
ACAD Stock  USD 26.71  0.01  0.04%   
ACADIA Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ACADIA Pharmaceuticals' valuation are provided below:
Gross Profit
617.8 M
Profit Margin
0.2494
Market Capitalization
4.5 B
Enterprise Value Revenue
3.5573
Revenue
1 B
There are over one hundred nineteen available fundamental measures for ACADIA Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of ACADIA Pharmaceuticals' latest performance against the performance from 2010 to 2025 to make sure the company is sustainable in the coming quarters. The current year's Market Cap is expected to grow to about 1.9 B. The current year's Enterprise Value is expected to grow to about 1.8 B

ACADIA Pharmaceuticals Total Revenue

1.01 Billion

Check ACADIA Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ACADIA Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 8 M, Selling General Administrative of 512.8 M or Total Revenue of 1 B, as well as many indicators such as Price To Sales Ratio of 3.02, Dividend Yield of 0.0 or PTB Ratio of 4.46. ACADIA financial statements analysis is a perfect complement when working with ACADIA Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with ACADIA Stock
Check out the analysis of ACADIA Pharmaceuticals Correlation against competitors.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

ACADIA Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.2 B1.2 B527.2 M
Slightly volatile
Short and Long Term Debt Total54.6 M52 M26.5 M
Slightly volatile
Common Stock Shares Outstanding85.2 M166.4 M112.4 M
Slightly volatile
Liabilities And Stockholders Equity1.2 B1.2 B527.2 M
Slightly volatile
Non Current Liabilities Total63.1 M60.1 M24.9 M
Slightly volatile
Total Liabilities477.7 M455 M132.7 M
Slightly volatile
Other Current Liabilities374.5 M356.7 M92.5 M
Slightly volatile
Total Current Liabilities414.6 M394.9 M105 M
Slightly volatile
Property Plant And Equipment Net53.3 M50.8 M23.3 M
Slightly volatile
Current Deferred Revenue1.3 M1.4 M1.4 M
Slightly volatile
Accounts Payable17 M16.2 M6.9 M
Slightly volatile
Cash335.6 M319.6 M139.7 M
Slightly volatile
Non Current Assets Total261.9 M249.4 M58.8 M
Slightly volatile
Cash And Short Term Investments793.8 M756 M404.6 M
Slightly volatile
Common Stock Total Equity19.3 K18.4 K12.3 K
Slightly volatile
Short Term Investments458.2 M436.4 M265 M
Slightly volatile
Other Current Assets58.5 M55.7 M18.1 M
Slightly volatile
Property Plant And Equipment Gross64.1 M61 M25.2 M
Slightly volatile
Total Current Assets985.2 M938.3 M467.3 M
Slightly volatile
Short Term Debt10.5 M10 M5.2 M
Slightly volatile
Common Stock9.5 K18.4 K11.6 K
Slightly volatile
Property Plant Equipment74.4 M70.8 M22.6 M
Slightly volatile
Other Liabilities11 M10.4 M3.8 M
Slightly volatile
Net Tangible Assets403.1 M460.5 M355.3 M
Slightly volatile
Capital Surpluse1.6 B3.1 B1.6 B
Slightly volatile
Warrants14.1 M15.9 M17.3 M
Slightly volatile
Net Receivables109.9 M104.7 M37.1 M
Slightly volatile
Non Current Liabilities Other13.5 M18.1 M7.8 M
Slightly volatile
Net Invested Capital583.9 M732.8 M448.6 M
Slightly volatile
Net Working Capital535.9 M543.4 M419 M
Slightly volatile
Long Term Investments2 M2.6 M1.7 M
Slightly volatile
Capital Stock17.1 K18.4 K15 K
Slightly volatile
Capital Lease Obligations51.6 M52 M26.3 M
Slightly volatile

ACADIA Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative512.8 M488.4 M233.4 M
Slightly volatile
Total Revenue1 B957.8 M303.2 M
Slightly volatile
Other Operating Expenses763.4 M727 M408.9 M
Slightly volatile
Research Development318.4 M303.2 M173.5 M
Slightly volatile
Total Operating Expenses677.4 M645.2 M389 M
Slightly volatile
Depreciation And Amortization16.7 M15.9 M3.7 M
Slightly volatile
Cost Of Revenue85.9 M81.8 M31.7 M
Slightly volatile
Tax Provision33.2 M31.6 M5.3 M
Slightly volatile
Interest Income26.7 M25.5 M6.9 M
Slightly volatile
Net Interest Income26.7 M25.5 M7.7 M
Slightly volatile
Selling And Marketing Expenses10.3 M10.8 M14.6 M
Slightly volatile
Reconciled Depreciation16.7 M15.9 M4.6 M
Slightly volatile

ACADIA Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow344.8 M328.4 M142.5 M
Slightly volatile
Begin Period Cash Flow204.1 M194.4 M113.8 M
Slightly volatile
Depreciation16.7 M15.9 M3.7 M
Slightly volatile
Total Cash From Financing Activities6.5 M6.8 M114.7 M
Pretty Stable
Stock Based Compensation63.7 M67 M195.6 M
Slightly volatile
Sale Purchase Of Stock19.8 M20.9 M116.3 M
Pretty Stable
Change To Netincome56.3 M71.2 M50.3 M
Slightly volatile
Issuance Of Capital Stock6.5 M6.8 M204.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.023.17495.4 K
Pretty Stable
Days Sales Outstanding37.939.89751.6 K
Slightly volatile
Stock Based Compensation To Revenue0.06650.0782.2166
Slightly volatile
Capex To Depreciation0.03130.03292.272
Pretty Stable
EV To Sales2.752.89555.3 K
Pretty Stable
Inventory Turnover1.983.72871.9087
Slightly volatile
Days Of Inventory On Hand93.097.8896238
Slightly volatile
Payables Turnover4.85.054413.6344
Slightly volatile
Sales General And Administrative To Revenue0.460.49112
Pretty Stable
Research And Ddevelopement To Revenue0.30.3166110
Pretty Stable
Capex To Revenue5.0E-45.0E-42.3687
Pretty Stable
Cash Per Share4.134.5623.4869
Very volatile
Days Payables Outstanding10972.2142121
Slightly volatile
Intangibles To Total Assets0.110.10080.0367
Slightly volatile
Current Ratio2.262.37639.1785
Slightly volatile
Receivables Turnover4.879.14854.5238
Slightly volatile
Graham Number5.710.4910.6486
Very volatile
Capex Per Share0.0030.00320.0598
Very volatile
Revenue Per Share6.075.77972.1701
Slightly volatile
Interest Debt Per Share0.30.31380.4835
Slightly volatile
Debt To Assets0.08070.04380.0424
Pretty Stable
Operating Cycle1311381.7 K
Slightly volatile
Days Of Payables Outstanding10972.2142121
Slightly volatile
Ebt Per Ebit1.071.11820.9801
Very volatile
Quick Ratio2.22.32079.126
Slightly volatile
Net Income Per E B T0.810.87750.9958
Pretty Stable
Cash Ratio0.770.80942.4828
Slightly volatile
Days Of Inventory Outstanding93.097.8896238
Slightly volatile
Days Of Sales Outstanding37.939.89751.6 K
Slightly volatile
Fixed Asset Turnover15.918.859522.0849
Pretty Stable
Debt Ratio0.08070.04380.0424
Pretty Stable
Price Sales Ratio3.023.17495.4 K
Pretty Stable
Asset Turnover0.850.80640.388
Slightly volatile

ACADIA Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.9 B1.8 B1.7 B
Slightly volatile
Enterprise Value1.8 B1.7 B1.6 B
Slightly volatile

ACADIA Fundamental Market Drivers

Forward Price Earnings41.3223
Cash And Short Term Investments756 M

ACADIA Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ACADIA Pharmaceuticals Financial Statements

ACADIA Pharmaceuticals stakeholders use historical fundamental indicators, such as ACADIA Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although ACADIA Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in ACADIA Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on ACADIA Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ACADIA Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.4 M1.3 M
Total Revenue957.8 M1 B
Cost Of Revenue81.8 M85.9 M
Stock Based Compensation To Revenue 0.07  0.07 
Sales General And Administrative To Revenue 0.49  0.46 
Research And Ddevelopement To Revenue 0.32  0.30 
Revenue Per Share 5.78  6.07 
Ebit Per Revenue 0.24  0.25 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C
When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:
How To Invest In ACADIA
Details
Is ACADIA Stock a good investment?
Details
What is ACADIA Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of ACADIA Pharmaceuticals Correlation against competitors.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.128
Earnings Share
1.55
Revenue Per Share
6.251
Quarterly Revenue Growth
0.113
Return On Assets
0.0511
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY